HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Yasuo Terauchi Selected Research

Glucagon-Like Peptide 1 (GLP 1)

4/2023Use of iGlarLixi for the Management of Type 2 Diabetes in Japanese Clinical Practice: Prior Treatment Subgroup Analysis of the SPARTA Japan Study.
9/2020Effect of liraglutide on lipids in patients with type 2 diabetes: a pilot study.
1/2020Benefits of the fixed-ratio combination of insulin glargine 100 units/mL and lixisenatide (iGlarLixi) in Japanese people with type 2 diabetes: A subgroup and time-to-control analysis of the LixiLan JP phase 3 trials.
1/2019PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes.
1/2018Efficacy and Safety of GPR119 Agonist DS-8500a in Japanese Patients with Type 2 Diabetes: a Randomized, Double-Blind, Placebo-Controlled, 12-Week Study.
10/2017Incretin Kinetics Before and After Miglitol in Japanese Patients With Late Dumping Syndrome.
6/2012Miglitol administered before breakfast increased plasma active glucagon-like peptide-1 (GLP-1) levels after lunch in patients with type 2 diabetes treated with sitagliptin.
1/2010Effects of miglitol, sitagliptin or their combination on plasma glucose, insulin and incretin levels in non-diabetic men.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Yasuo Terauchi Research Topics

Disease

140Type 2 Diabetes Mellitus (MODY)
04/2024 - 01/2002
71Insulin Resistance
01/2023 - 01/2002
43Body Weight (Weight, Body)
04/2024 - 07/2002
29Obesity
01/2023 - 01/2002
24Hypoglycemia (Reactive Hypoglycemia)
03/2024 - 04/2009
18Glucose Intolerance
10/2021 - 07/2002
15Inflammation (Inflammations)
01/2023 - 09/2002
14Non-alcoholic Fatty Liver Disease
01/2023 - 05/2007
13Hyperglycemia
11/2023 - 04/2003
12Diabetes Mellitus
12/2023 - 09/2006
11Fatty Liver
05/2024 - 05/2011
9Fibrosis (Cirrhosis)
04/2015 - 03/2005
8Albuminuria
04/2024 - 10/2007
8Hyperinsulinism (Hyperinsulinemia)
01/2023 - 06/2004
7Neoplasms (Cancer)
11/2023 - 06/2005
7Dyslipidemias (Dyslipidemia)
05/2023 - 06/2010
6Cardiovascular Diseases (Cardiovascular Disease)
01/2022 - 10/2012
6Metabolic Syndrome (Dysmetabolic Syndrome X)
01/2017 - 10/2003
6Alcoholic Fatty Liver
02/2016 - 06/2010
6Hypertrophy
08/2008 - 01/2002
5Weight Loss (Weight Reduction)
06/2023 - 07/2014
5Liver Diseases (Liver Disease)
01/2023 - 01/2011
5Hypertension (High Blood Pressure)
04/2022 - 08/2005
5Type 1 Diabetes Mellitus (Autoimmune Diabetes)
06/2021 - 03/2017
5Carcinogenesis
02/2016 - 06/2005
5Atherosclerosis
10/2015 - 07/2002
4Drug-Related Side Effects and Adverse Reactions
01/2023 - 01/2016
4Heart Failure
01/2022 - 01/2016
4Atrophy
10/2020 - 01/2014
4Insulinoma
01/2017 - 03/2009
4Hyperplasia
01/2017 - 06/2004
4Hyperlipidemias (Hyperlipidemia)
01/2014 - 04/2005
3Diabetic Nephropathies (Diabetic Nephropathy)
04/2024 - 01/2019
3Hyperthyroidism
01/2023 - 01/2014
3Body Weight Changes
01/2022 - 01/2015

Drug/Important Bio-Agent (IBA)

76Glucose (Dextrose)FDA LinkGeneric
12/2023 - 01/2003
61Insulin (Novolin)FDA Link
05/2024 - 01/2002
32LipidsIBA
09/2020 - 01/2003
22Sitagliptin Phosphate (Januvia)FDA Link
12/2019 - 01/2010
21Blood Glucose (Blood Sugar)IBA
04/2024 - 04/2003
16Hypoglycemic Agents (Hypoglycemics)IBA
04/2023 - 12/2003
16AdiponectinIBA
09/2018 - 07/2002
15PPAR gammaIBA
12/2008 - 01/2002
14Triglycerides (Triacylglycerol)IBA
02/2019 - 02/2005
13Insulin Receptor Substrate ProteinsIBA
01/2020 - 11/2002
12SodiumIBA
12/2023 - 08/2005
12Glycated Hemoglobin (Glycosylated Hemoglobin)IBA
12/2023 - 01/2016
10Insulin Glargine (Lantus)FDA Link
02/2024 - 03/2017
10LiraglutideFDA Link
06/2023 - 07/2012
10Hemoglobins (Hemoglobin)IBA
04/2022 - 01/2014
10LDL CholesterolIBA
02/2020 - 01/2007
9Sodium-Glucose Transporter 2 InhibitorsIBA
04/2024 - 03/2014
9LeptinIBA
01/2023 - 01/2003
9GlucokinaseIBA
10/2021 - 06/2004
8Glucagon-Like Peptide 1 (GLP 1)IBA
04/2023 - 01/2010
8ipragliflozinIBA
09/2020 - 01/2016
8miglitol (Glyset)FDA Link
02/2020 - 01/2010
7CreatinineIBA
04/2024 - 02/2015
7Metformin (Glucophage)FDA LinkGeneric
01/2023 - 05/2010
7lixisenatideIBA
12/2022 - 01/2016
7Insulin ReceptorIBA
10/2022 - 06/2003
7Dipeptidyl-Peptidase IV InhibitorsIBA
08/2022 - 04/2011
7oxidized low density lipoproteinIBA
02/2020 - 01/2007
6AlbuminsIBA
04/2024 - 01/2014
6Glucagon-Like Peptide-1 Receptor AgonistsIBA
04/2024 - 01/2019
6Fatty Acids (Saturated Fatty Acids)IBA
01/2023 - 01/2003
6CholesterolIBA
09/2020 - 09/2009
6Glucagon-Like Peptide-1 ReceptorIBA
11/2019 - 01/2014
6Pioglitazone (Actos)FDA Link
08/2017 - 09/2002
6Ezetimibe (Zetia)FDA Link
01/2014 - 09/2009
5semaglutideIBA
06/2023 - 01/2018
5EnzymesIBA
01/2023 - 06/2004
5glimepiride (Amarel)FDA LinkGeneric
01/2022 - 10/2011
5Biomarkers (Surrogate Marker)IBA
12/2021 - 05/2007
5CanagliflozinIBA
12/2021 - 03/2019
5HDL CholesterolIBA
12/2021 - 01/2007
56- ((4- ethylphenyl)methyl)- 3',4',5',6'- tetrahydro- 6'- (hydroxymethyl)spiro(isobenzofuran- 1(3H),2'- (2H)pyran)- 3',4',5'- triolIBA
11/2019 - 03/2014
5Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA
01/2019 - 01/2012
5Hormones (Hormone)IBA
01/2018 - 07/2002
5Glucagon (Glukagon)FDA Link
10/2017 - 11/2011
4SymportersIBA
12/2023 - 02/2016
4dulaglutideIBA
06/2023 - 01/2014
4Therapeutic UsesIBA
01/2023 - 05/2010
4anagliptinIBA
08/2022 - 01/2015
4alogliptinIBA
08/2022 - 06/2013
4empagliflozinIBA
01/2022 - 06/2014
43- (8- amino- 1- (2- phenylquinolin- 7- yl)imidazo(1,5- a)pyrazin- 3- yl)- 1- methylcyclobutanolIBA
10/2020 - 06/2014
4IncretinsIBA
10/2017 - 11/2011
4LigandsIBA
04/2008 - 09/2002
4Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
12/2003 - 09/2002
3Sodium-Glucose Transport ProteinsIBA
10/2023 - 04/2014
3C-Reactive ProteinIBA
11/2021 - 06/2006
3insulin degludecIBA
01/2021 - 03/2017
3Apolipoproteins E (ApoE)IBA
01/2021 - 01/2003
3IGF Type 1 Receptor (IGF 1 Receptor)IBA
10/2020 - 06/2014
3Glycoside Hydrolase InhibitorsIBA
02/2020 - 09/2009
3SteroidsIBA
06/2019 - 01/2014

Therapy/Procedure

41Glycemic Control
02/2024 - 08/2007
34Therapeutics
01/2023 - 08/2007
5Injections
04/2023 - 01/2009